Stereotaxis (STXS) 10-Q 10 May 17 2017 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2017	Apr. 28, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	Stereotaxis, Inc.
Entity Filer Category	Smaller Reporting Company
Entity Central Index Key	1,289,340
Trading Symbol	stxs
Amendment Flag	false
Document Type	10-Q
Document Fiscal Period Focus	Q1
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		22,546,867

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 5,739,124	$ 8,501,392
Accounts receivable, net of allowance of $600,567 and $379,817 in 2017 and 2016, respectively	5,316,935	4,665,959
Inventories	5,658,369	5,381,103
Prepaid expenses and other current assets	911,829	855,295
Total current assets	17,626,257	19,403,749
Property and equipment, net	935,095	1,086,244
Intangible assets, net	386,738	436,569
Other assets	41,394	39,241
Total assets	18,989,484	20,965,803
Current liabilities:
Accounts payable	2,215,111	2,623,010
Accrued liabilities	4,085,696	4,491,164
Deferred revenue	9,374,879	8,751,336
Warrants	16,657,699	19,787,007
Total current liabilities	32,333,385	35,652,517
Long-term deferred revenue	435,542	522,329
Other liabilities	320,545	320,409
Total liabilities	33,089,472	36,495,255
Convertible Preferred stock:
Convertible Preferred stock, par value $0.001; 10,000,000 shares authorized ; 23,900 shares outstanding at 2017 and 2016	5,960,475	5,960,475
Stockholders' deficit:
Common stock, par value $0.001; 300,000,000 shares authorized, 22,545,128 and 22,063,582 shares issued at 2017 and 2016, respectively	22,545	22,064
Additional paid in capital	450,191,422	449,939,406
Treasury stock, 4,015 shares at 2017 and 2016	(205,999)	(205,999)
Accumulated deficit	(470,068,431)	(471,245,398)
Total stockholders' deficit	(20,060,463)	(21,489,927)
Total liabilities and stockholders' deficit	$ 18,989,484	$ 20,965,803

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Balance Sheets [Abstract]
Accounts receivable, allowance	$ 600,567	$ 379,817
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	23,900	23,900
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	22,545,128	22,063,582
Treasury stock, shares	4,015	4,015

Statements Of Operations

Statements Of Operations - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue:
Systems	$ 218,895	$ 2,075,019
Disposables, service and accessories	6,758,777	6,572,987
Total revenue	6,977,672	8,648,006
Cost of revenue:
Systems	220,443	1,083,099
Disposables, service and accessories	1,036,182	1,097,715
Total cost of revenue	1,256,625	2,180,814
Gross margin	5,721,047	6,467,192
Operating expenses:
Research and development	1,158,434	1,473,086
Sales and marketing	3,625,601	3,894,113
General and administrative	2,839,870	2,586,791
Total operating expenses	7,623,905	7,953,990
Operating loss	(1,902,858)	(1,486,798)
Other income	3,129,308	31,294
Interest income	7	222
Interest expense	(49,490)	(819,019)
Net income (loss)	1,176,967	(2,274,301)
Cumulative dividend on convertible preferred stock	(363,188)
Net income attributable to convertible preferred stock	(509,323)
Earnings (net loss) attributable to common stockholders	$ 304,456	$ (2,274,301)
Earnings (net loss) per common share:
Basic	$ 0.01	$ (0.11)
Diluted	$ 0.01	$ (0.11)
Weighted average shares used in computing earnings (net loss) per common share:
Basic	22,318,000	21,611,612
Diluted	22,331,683	21,611,612

Statements Of Cash Flows

Statements Of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities
Net earnings (loss)	$ 1,176,967	$ (2,274,301)
Adjustments to reconcile net earnings (loss) to cash used in operating activities:
Depreciation	140,848	97,394
Amortization of intangibles	49,831	49,830
Amortization of deferred finance costs	24,657	54,937
Share-based compensation	243,161	270,102
Loss on asset disposal	14,598
Adjustment of warrants	(3,129,308)	(31,294)
Changes in operating assets and liabilities:
Accounts receivable	(650,976)	(21,190)
Inventories	(277,266)	57,919
Prepaid expenses and other current assets	18,809	(407,930)
Other assets	(2,153)	(648)
Accounts payable	(407,899)	202,111
Accrued liabilities	(405,468)	(812,995)
Deferred revenue	536,756	(1,045,958)
Other liabilities	136	(5,170)
Net cash used in operating activities	(2,667,307)	(3,867,193)
Cash flows from investing activities
Purchase of fixed assets	(4,297)
Net cash used in investing activities	(4,297)
Cash flows from financing activities
Payments of deferred financing costs	(100,000)	(100,000)
Proceeds from (payments of) Healthcare Royalty Partners debt		(30,830)
Proceeds from issuance of stock, net of issuance costs	9,336	7,392
Net cash provided by (used in) financing activities	(90,664)	(123,438)
Net increase (decrease) in cash and cash equivalents	(2,762,268)	(3,990,631)
Cash and cash equivalents at beginning of period	8,501,392	5,593,582
Cash and cash equivalents at end of period	$ 5,739,124	$ 1,602,951

Description Of Business

Description Of Business	3 Months Ended
	Mar. 31, 2017
Description Of Business [Abstract]
Description Of Business	1. Description of Business Stereotaxis designs, manufactures and markets the Epoch Solution, which is an advanced remote robotic navigation system for use in a hospital’s interventional surgical suite, or “interventional lab”, that we believe revolutionizes the treatment of arrhythmias and coronary artery disease by enabling enhanced safety, efficiency and efficacy for catheter-based, or interventional, procedures. The Epoch Solution is comprised of the Niobe ES Remote Magnetic Navigation System (“ Niobe ES system”), Odyssey Information Management Solution (“ Odyssey Solution”), and the Vdrive Robotic Navigation System (“ Vdrive system”), and related devices. The Niobe system is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, efficient procedures and reduced x-ray exposure. As of March 31, 2017, the Company had an installed base of 129 Ni obe ES systems. In addition to the Niobe system and its components, Stereotaxis also has developed the Odyssey Solution, which consolidates all lab information enabling doctors to focus on the patient for optimal procedure efficiency. The system also features a remote viewing and recording capability called Odyssey Cinema , which is an innovative solution delivering synchronized content for optimized workflow, advanced care and improved productivity. This tool includes an archiving capability that allows clinicians to store and replay entire procedures or segments of procedures. This information can be accessed from locations throughout the hospital local area network and over the global Odyssey Network providing physicians with a tool for clinical collaboration, remote consultation and training. Our Vdrive system provides navigation and stability for diagnostic and therapeutic devices designed to improve interventional procedures. The Vdrive system complements the Niobe ES system control of therapeutic catheters for fully remote procedures and enables single-operator workflow and is sold as two options, the Vdrive system and the Vdrive Duo system. In addition to the Vdrive system and the Vdrive Duo system, we also manufacture and market various disposable components which can be manipulated by these systems. We promote the full Epoch Solution in a typical hospital implementation, subject to regulatory approvals or clearances. The full Epoch Solution implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure, equipment service costs beyond warranty period, and software licenses. In hospitals where the full Epoch Solution has not been implemented, equipment upgrade or expansion can be implemented upon purchasing of the necessary upgrade or expansion. The core components of Stereotaxis systems, such as Niobe system, Odyssey Solution, Cardiodrive and various disposable interventional devices have received regulatory clearance in the U.S., Europe, Canada, China, Japan and various other countries. We have received the regulatory clearance, licensing and/or CE Mark approvals that allow us to market the Vdrive and Vdrive Duo systems with the V-CAS , V-Loop and V-Sono devices in the U.S., Canada and European Union. The V-CAS Deflect catheter advancement system has been CE Marked for sale in the European Union. The Company believes the cash on hand at March 31, 2017 as well as expected borrowing capacity available will be sufficient to meet its obligations as they become due in the ordinary course of business for at least 12 months following the date these financial statements are issued. This evaluation assumes the Company is able to renew and has the ability to borrow under its asset based revolving credit facility which matures on March 31, 2018. The Company expects to be able to renew this facility at similar terms, as it has successfully done so in the past. There is no assurance that the revolving credit facility will be renewed in a timely manner, in amounts that are sufficient to meet the Company’s obligations as they become due, or on terms acceptable to the Company, or at all. The Company has sustained operating losses throughout its corporate history and expects that its 2017 expenses will exceed its 2017 gross margin. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations or expense reductions are in place. Accordingly, management has analyzed its planned operations to evaluate the Company’s ability to continue as a going concern. The Company’s liquidity needs will be largely determined by the success of clinical adoption within the installed base of Niobe systems as well as by new placements of capital systems. The Company’s plans, which are probable of effectively being implemented and improving the liquidity conditions, primarily include its ability to control the timing and spending of its operating expenses and raising additional funds through capital transactions. Specifically, cash outflows for operating expenses could be reduced or delayed by transitioning certain cash payments to stock payments, by reducing project expenses, or by reducing headcount. The Company also may consider raising cash through capital transactions, which could include either debt or equity financing.

Summary Of Significant Accounti

Summary Of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2017
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited financial statements of Stereotaxis, Inc. have been prepared in accordance with generally accepted accounting principles for interim financial information and the instructions to Form 10-Q. Accordingly, they do not include all the disclosures required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, they include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Operating results for the three month period ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ended December 31, 2017 or for future operating periods. These interim financial statements and the related notes should be read in conjunction with the annual financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the Securities and Exchange Commission (SEC) on March 16, 2017. Financial Instruments Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value. The Company measures certain financial assets and liabilities, including warrants, at fair value on a recurring basis. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). See Note 11 for additional details. Revenue and Costs of Revenue The Company accounts for revenue using Accounting Standards Codification Topic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 permits management to estimate the selling price of undelivered components of a bundled sale for which it is unable to establish vendor-specific objective evidence (“VSOE”) or third-party evidence (“TPE”). This requires management to record revenue for certain elements of a transaction even though it might not have delivered other elements of the transaction, for which it was unable to meet the requirements for establishing VSOE or TPE. The Company believes that the guidance significantly improves the reporting of these types of transactions to more closely reflect the underlying economic circumstances. This guidance also prohibits the use of the residual method for allocating revenue to the various elements of a transaction and requires that the revenue be allocated proportionally based on the relative estimated selling prices. Under our revenue recognition policy, a portion of revenue for Niobe systems, Vdrive systems and certain Odyssey systems is recognized upon delivery, provided that title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. Revenue is recognized for other types of Odyssey systems upon completion of installation, since there are no qualified third party installers. When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since these arrangements do not include an installation element or right of return privileges. The Company does not recognize revenue in situations in which inventory remains at a Stereotaxis warehouse or in situations in which title and risk of loss have not transferred to the customer. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue. Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multiple-deliverable arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. We recognize revenue from disposable device sales or accessories upon shipment and establish an appropriate reserve for returns. The return reserve, which is applicable only to disposable devices, is estimated based on historical experience which is periodically reviewed and updated as necessary. In the past, changes in estimate have had only a de minimis effect on revenue recognized in the period. We believe that the estimate is not likely to change significantly in the future. Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred. Share-Based Compensation The Company accounts for its grants of stock options, stock appreciation rights, restricted shares, and restricted stock units and for its employee stock purchase plan in accordance with the provisions of general accounting principles for share-based payments. These accounting principles require the determination of the fair value of the share-based compensation at the grant date and the recognition of the related expense over the period in which the share-based compensation vests. The Company utilizes the Black-Scholes valuation model to determine the fair value of stock options and stock appreciation rights at the date of grant. The resulting compensation expense is recognized over the requisite service period, which is generally four years. Restricted shares granted to employees are valued at the fair market value at the date of grant. The Company amortizes the fair market value to expense over the service period. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives. Net Earnings (Loss) per Common Share (“EPS”) Basic net income ( loss) per share is computed by dividing net income (loss) attributable to common shareholders by the number of common shares outstanding during the period. We apply the two-class method to calculate basic and diluted net income (loss) per share of common stock, as our Convertible Preferred Stock is a participating security. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been av ailable to common stockholders. In periods where there is a net loss, the two-class method of computing earnings per share does not apply as our Convertible Preferred Stock does not contractually participate in our losses. We compute diluted net income (loss) per common share using net income (loss) as the “control number” in determining whether potential common shares are dilutive, after giving consideration to all potentially dilutive common shares, including stock options, warrants, unvested restricted stock units outstanding during the period and potential issuance of stock upon the conversion of our Convertible Preferred Stock issued and outstanding during the period, except where the effect of such securities would be antidilutive. The following table sets forth the computation of basic and diluted EPS:    Three months ended March 31,  2017 2016  Net income (loss) $ 1,176,967 $ (2,274,301)  Cumulative dividend on convertible preferred stock (363,188) -  Net income attributable to convertible preferred stock (509,323) -  Earnings (net loss) attributable to common stockholders $ 304,456 $ (2,274,301)   Shares used for basic EPS-weighted average shares 22,318,000 21,611,612  Effect of dilutive securities: - -  Restricted Stock Units 13,683 -  Stock Options, Appreciation Rights and Warrants - -   Weighted average shares used in computing earnings (net loss) per share 22,331,683 21,611,612  Basic EPS $ 0.01 $ (0.11)  Diluted EPS $ 0.01 $ (0.11)  The following potential common shares were excluded from diluted EPS for the three months ended March 31, 2017 as they were antidilutive: 665,477 stock options and stock appreciation rights , 671, 929 restricted stock units, and 38,887,708 warrants . In addition, the Company did not include any portion of unearned restricted stock units, outstanding options, stock appreciation rights or warrants in the calculation of diluted loss per common share for the three months ended March 31, 2016 because all such securities are anti-dilutive for the period . The Company had no unearned restricted shares during either period. As of March 31, 2017, the Company had 665,477 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $8.41 per share, 38,887,708 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $0.83 per share, 37,892,041 shares of common stock issuable upon the conversion of Series A Convertible Preferred Stock and accumulated dividends at an exercise price of $0.65 per share, and 685,612 shares of unvested restricted share units. Recently Issued Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU” or “Update”) No. 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.” This amendment is intended to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, forfeitures, and classification on the statement of cash flows. This update is effective for fiscal years beginning after December 15, 2016 (January 1, 2017 for the Company) and interim periods within those fiscal years, with earlier application permitted. The Company has adopted this guidance in the first quarter of 2017. The adoption of ASU 2016-09 did not materially impact the Company’s consolidated financial position, results of operations, equity or cash flows. In July 2015, the FASB issued ASU No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory” regarding the subsequent measurement of inventory as part of its Simplification Initiative. This standard is effective for public companies for fiscal years beginning after December 15, 2016 (January 1, 2017 for the Company), including interim periods within those fiscal years. This Update should be applied prospectively, and early application is permitted as of the beginning of an interim or annua l reporting period. The Company adopted this accounting standard update in the first quarter of 2017. The adoption of ASU 2015-1 1 did not materially impact the company ’s results of operations, financial conditions, cash flows, or financial statement presentation. In February 2016, the FASB issued ASU 2016-02, “Leases (ASC 842),” which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840 Leases. The standard is effective for interim and annual periods beginning after December 31, 2018 (January 1, 2019 for the Company), with early adoption permitted. The Company is in the process of evaluating the impact of this accounting standard update. In August 2014, the Financial Accounting Standards Board (“FASB”) issued AS U No. 2014-15, to communicate amendments to FASB Account Standards Codification Subtopic 205-40, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The ASU requires management to evaluate relevant conditions, events and certain management plans that are known or reasonably knowable as of the evaluation date when determining whether substantial doubt about an entity’s ability to continue as a going concern exists. Management will be required to make this evaluation for both annual and interim reporting periods. Management will have to make certain disclosures if it concludes that substantial doubt exists or when it plans to alleviate substantial doubt about the entity’s ability to continue as a going concern. The standard is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in the first quarter of 2017 (December 31, 2016 for the Company). Early adoption is permitted. The Company adopted this accounting standard update effective December 31, 2016 and provided the relevant disclosures in Note 1. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers,” which converges the FASB’s and the International Accounting Standards Board’s current standards on revenue recognition. The standard provides companies with a single model to use in accounting for revenue arising from contracts with customers and supersedes current revenue guidance. The standard is effective for annual and interim periods beginning after December 15, 2017 (January 1, 2018 for the Company). Early adoption is not permitted. The standard permits companies to either apply the adoption to all periods presented, or apply the requirements in the year of adoption through a cumulative adjustment. The Company will adopt ASU 2014-09 during the first quarter of 2018 and anticipates using the modified retrospective method that will result in a cumulative effect adjustment as of the date of adoption. Upon initial evaluation, management does not anticipate a significant change to its existing units of accounting which include systems, disposables and other accessories, royalty and other recurring revenue. The Company continues to evaluate other areas of the standard and its effect on the Corporation’s financial statements.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2017
Inventories [Abstract]
Inventories	3. Inventories Inventories consist of the following:    March 31, 2017 December 31, 2016   Raw materials $ 2,476,142 $ 2,397,430  Work in process 349,597 341,125  Finished goods 3,126,728 2,915,162  Reserve for obsolescence (294,098) (272,614)  Total inventory $ 5,658,369 $ 5,381,103 

Prepaid Expenses And Other Curr

Prepaid Expenses And Other Current Assets	3 Months Ended
	Mar. 31, 2017
Prepaid Expenses And Other Current Assets [Abstract]
Prepaid Expenses And Other Current Assets	4. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following:       March 31, 2017 December 31, 2016   Prepaid expenses $ 496,267 $ 575,886  Deferred financing costs 100,000 24,658  Deposits 356,956 293,992  Total prepaid expenses and other assets 953,223 894,536  Less: Noncurrent prepaid expenses and other assets (41,394) (39,241)  Total current prepaid expenses and other assets $ 911,829 $ 855,295                

Property And Equipment

Property And Equipment	3 Months Ended
	Mar. 31, 2017
Property And Equipment [Abstract]
Property And Equipment	5. Property and Equipment Property and equipment consist of the following:    March 31, December 31,  2017 2016   Equipment $ 8,234,491 $ 8,397,528  Equipment held for lease 303,412 303,412  Leasehold improvements 2,714,486 2,719,860  11,252,389 11,420,800  Less: Accumulated depreciation (10,317,294) (10,334,556)  Net property and equipment $ 935,095 $ 1,086,244 

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2017
Intangible Assets [Abstract]
Intangible Assets	6. Intangible Assets  As of March 3 1 , 201 7 , the Company had total intangible assets of $3,221,069 . Accumulated amortization at March 3 1, 2017 , was $2,834,331.   

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2017
Accrued Liabilities [Abstract]
Accrued Liabilities	7. Accrued Liabilities Accrued liabilities consist of the following:    March 31, December 31,  2017 2016   Accrued salaries, bonus, and benefits $ 2,274,587 $ 2,452,183  Accrued rent 723,770 965,412  Accrued licenses and maintenance fees 559,605 561,450  Accrued warranties 193,064 222,845  Accrued taxes 265,901 219,017  Accrued professional services 116,700 180,450  Other 272,614 210,216  Total accrued liabilities 4,406,241 4,811,573  Less: Long term accrued liabilities (320,545) (320,409)  Total current accrued liabilities $ 4,085,696 $ 4,491,164   Our primary company facilities are located in St. Louis, Missouri where we currently lease approximately 52,000 square feet of office and 12,000 square feet of demonstration and assembly space. In the third quarter of 2013, the Company modified the existing lease agreement to terminate approximately 13,000 square feet of unimproved space. The costs associated with the termination were $515,138 and were accrued as a rent liability as of September 30, 2013. As of March 3 1, 2017 , the remaining accrued costs associated with the termination were $160,065 . In the fourth quarter of 2015 , the Company entered an agreement to sublease 3,152 square feet of the first floor office space through December 31, 2018 . In July 2016, the Company and the subtenant mutually agreed to an early termination of the sublease, effective July 31, 2016 . In August 2016 the Company entered into an agreement to sublease approximately 11,000 square feet of office space through December 31, 2018 . T he costs associated with the sublease were $40,972 and were accrued as a rent li ability as of August 31, 2016 . In January 2017, as part of the sublease agreement, the Company subleased an additional 16,000 square feet through December 31, 2018 . The costs associated with the January sublease were $28,208 . As of March 3 1, 2017 , the remaining accrued costs associated with the termination were $44,687.   

Deferred Revenue

Deferred Revenue	3 Months Ended
	Mar. 31, 2017
Deferred Revenue [Abstract]
Deferred Revenue	8. Deferred Revenue Deferred revenue consists of the following:    March 31, December 31,  2017 2016   Product shipped, revenue deferred $ 467,383 $ 549,709  Customer deposits 2,910,000 2,910,000  Deferred service and license fees 6,433,038 5,813,956  Total deferred revenue 9,810,421 9,273,665  Less: Long-term deferred revenue (435,542) (522,329)  Total current deferred revenue $ 9,374,879 $ 8,751,336 

Long-Term Debt And Credit Facil

Long-Term Debt And Credit Facilities	3 Months Ended
	Mar. 31, 2017
Long-Term Debt And Credit Facilities [Abstract]
Long-Term Debt And Credit Facilities	9. Long-Term Debt and Credit Facilities   Revolving Line of Credit The Company has had a working capital line of credit with its primary lender, Silicon Valley Bank, since 2004. The revolving line of credit is secured by substantially all of the Company’s assets. The maximum available under the line is $10.0 million subject to the value of collateralized assets. The Company is required under the revolving line of credit to maintain its primary operating account and the majority of its cash and investment balances in accounts with its primary lender. The facility was amended on March 27, 2015, extending the maturity date to March 31, 2018 and on May 10, 2016 , the Company and the primary lender agreed to modify certain financial covenants . The amended agreement requires the Company to maintain a liquidity ratio greater than 1.50 :1.00, excluding certain short term advances from the calculation, and a minimum tangible net worth of not less than ( no worse than) negative $24.0 million for the quarters ended June 30, 2016, September 30, 2016, December 31, 2016, March 31, 2017, June 30, 2017, and September 30, 2017; and not less than (no worse than) negative $24.5 million for the quarters ended December 31, 2017 and March 31, 2018. As of March 3 1 , 201 7 , the Company had no outstanding balance under the revolving line of credit. Draws on the line of credit are made based on the borrowing c apacity one week in arrears. As of March 3 1, 2017 , the Company had a borrowing capacity of $4.3 million based on the Company’s collateralized assets . The Comp any’s total liquidity as of March 3 1 , 201 7 , was $10.0 million which included cash and cash equivalents of $5.7 million. Healthcare Royalty Partners Debt In November 2011, the Company entered into a loan agreement with Healthcare Royalty Partners. Under the agreement the Company borrowed from Healthcare Royalty Partners $15 million. The Company was permitted to borrow up to an additional $5 million in the aggregate based on the achievement by the Company of certain milestones related to Niobe ES system sales in 2012. On August 8, 2012, the Company borrowed an additional $2.5 million based upon achievement of a milestone related to Niobe ES system sales for the nine months ended June 30, 2012. On January 31, 2013, the Company borrowed an additional $2.5 million based upon achievement of a milestone related to Niobe ES system sales for the twelve months ended D ecember 31, 2012. The loan was to be repaid through, and secured by, royalties payable to the Company under its Development, Alliance and Supply Agreement with Biosense Webster, Inc. (the “Biosense Agreement”). The Biosense Agreement relates to the development and distribution of magnetically enabled catheters used with Stereotaxis' Niobe ES system in cardiac ablation procedures. Under the terms of the agreement, Hea lthcare Royalty Partners was entitled to receive 100% of all royalties due to the Company under the Bios ense Agreement until the loan was re paid. The loan was a full recourse loan, scheduled to mature on December 31, 2018 , and included interest at an annual rate of 16% payable quarterly with royalties received under the Biosense Agreement. If the payments received by the Company under the Biosense Agreement were insufficient to pay all amounts of interest due on t he loan, then such deficiency would have increase d the outstanding principal amount on the lo an. The loan was also secured by certain assets and intellectual property of the Company. The agreement also contain ed customary affirmative and negative covenants. The use of payments due to the Company under the Biosense Agreement was approved by our primary lender. In September 2016, the Company extinguished the remainder of the debt of $18.1 million, net of deferred financing costs of approximately $0.3 million, as well as accrued interest of $0.5 million for $13.0 million based upon an agreement entered into with Healthcare Royalty Partners. After the loan obligation was repaid, the royalties under the Biosense Agreement will again be paid to the Company. As a result of the debt extinguishment, the company recognized a net gain of $5.6 million in fiscal 2016.

Convertible Preferred Stock And

Convertible Preferred Stock And Stockholders' Equity	3 Months Ended
	Mar. 31, 2017
Convertible Preferred Stock And Stockholders' Equity [Abstract]
Convertible Preferred Stock And Stockholders' Equity	10. Convertible Preferred Stock and Stockholders’ Equity The holders of common stock are entitled to one vote for each share held and to receive dividends whenever funds are legally available and when declared by the Board of Directors subject to the rights of holders of all classes of stock having priority rights as dividends and the conditions of the revolving line of credit agreement. No dividends have been declared or paid as of March 31, 2017. Convertible Preferred Stock and Warrants On September 26, 2016, the Company entered into a Securities Purchase Agreement with certain institutional and other accredited investors whereby it agreed to sell, for an aggregate purchase price of $24.0 million, (i) an aggregate of 24,000 shares of Series A Convertible Preferred Stock, par value $0.001 with a stated value of $1,000 per share which are convertible into shares of the Company’s common stock and (ii) warrants to purchase an aggregate of 36,923,078 shares of common stock. The transaction closed on September 29, 2016. The Company received net proceeds from the sale of the convertible preferred stock and warrants of $23.0 million, after offering expenses. The Company used $13.0 million of the funds to satisfy in full all amounts outstanding under the Loan Agreement with Healthcare Royalty Partners, as noted above, and anticipates using the remaining proceeds for general corporate purposes. The designations, preferences, powers and rights of the convertible preferred shares are set forth in a Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock (“Certificate of Designations”) filed with the Delaware Secretary of State. The convertible preferred shares are entitled to vote on an as-converted basis with the common stock, subject to specified beneficial ownership issuance limitations. The convertible preferred shares bear dividends at a rate of six percent ( 6% ) per annum, which are cumulative and accrue daily from the date of issuance on the $1,000 stated value. Such dividends will not be paid in cash except in connection with any liquidation, dissolution or winding up of the Company or any redemption of the convertible preferred shares. Instead the value of the accrued dividends is added to the liquidation preference of the convertible preferred shares and will increase the number of shares of common stock issuable upon conversion. Each convertible preferred share is convertible at the option of the holder from and after the date of issuance with no expiration date, at an initial conversion price of $0.65 per share, subject to adjustment in the event of stock splits, dividends, mergers, sales of all or substantially all of our assets or similar transactions, subject to specified beneficial ownership issuance limitations. Each holder of convertible preferred shares has the right to require us to redeem such holder’s convertible preferred shares upon the occurrence of specified events, which include certain business combinations, the sale of all or substantially all of the Company’s assets or the sale of more than 50% of the outstanding shares of the Company’s common stock. In addition, the Company has the right to redeem the convertible preferred shares in the event of a change of control as defined in the Certificate of Designations . The convertible preferred shares rank senior to our common stock as to distributions and payments upon the liquidation, dissolution and winding up of the Company. No such distributions or payments upon the liquidation, dissolution and winding up of the Company may be made to the holders of common stock unless and until the holders of convertible preferred shares have received the stated value of $1,000 per share plus any accrued and unpaid dividends. Until all convertible preferred shares have been converted or redeemed, no dividends may be paid on the common stock without the express written consent of the holders of a majority of the outstanding convertible preferred shares. In the event that dividends or other distributions of assets are made or paid by the Company to the holders of the common stock, the holders of convertible preferred shares are entitled to participate in such dividend or distribution on an as-converted basis. On the date of the issuance, the fair value of the convertible preferred stock was greater than the allocated proc eeds received for the Series A Convertible Preferred S tock. As such, the Company accounted for the beneficial conversion feature under ASC 470-20, Debt with Conversion feature under ASC 470-20, Debt with Conversion and Other Options. The Company recorded a deemed dividend charge of $6.1 million for the accretion of a discount on the Series A Convertible Preferred S tock. The deemed dividend was a non-cash transaction and is reflected below net loss to arrive at net loss available to common stockholders. Since the convertible preferred shares are subject to conditions for redemption that are outside the Company’s control, the convertible preferred shares are presently reported in the mezzanine section of the balance sheet . The warrants issued in conjunction with the convertible preferred stock have an exercise price equal to $0.70 per share subject to adjustments as provided under the terms of the warrants. The warrants are exercisable through September 29, 2021, subject to specified beneficial ownership issuance limitations. The warrants may be exercised by any holder on a cashless basis if, at any time after the date that is 180 days after the closing, the registration statement required by the Registration Rights Agreement is not effective and available for resale of all of the shares of common stock issuable upon exercise of such holder’s warrants. Due to the fact that the warrants are puttable upon the occurrence of certain events outside of the Company’s control, the warrants qualify as liabilities under ASC 480-10. The calculated fair value of the warrants is classified as a liability and is periodically re-measured with any changes in value recognized in “Other income (expense)” in the State ments of Operations. See Note 11 for additional details . On December 2, 2016 100 shares of convertible preferred stock plus accumulated dividends were converted into 155,439 common shares. Listing Transfer to OTCQX® Best Market On August 2, 2016, the Company received a determination letter from the Nasdaq Hearings Panel (the “Panel”) notifying the Company that its common stock would be delisted from The Nasdaq Capital Market (“Nasdaq”) and that suspension of trading in the shares would be effective at the open of business on August 4, 2016. The determination letter also indicated that Nasdaq would complete the delisting by filing a Form 25 Notification of Delisting with the Securities Exchange Commission, after applicable appeal periods have lapsed. The Panel made the determination to delist the Company’s common stock because the Company did not demonstrate compliance with the minimum $35 million market value of listed securities requirement for a period of ten consecutive trading days by August 1, 2016, as required by a decision previously issued by the Panel on May 2, 2016. The Company’s shares of common stock commenced trading on the OTCQX ® Best Market on August 4, 2016 under the Company’s current ticker symbol of “STXS.” Controlled Equity Offering The Company entered into a Controlled Equity Offering SM sales agreement (the “Sales Agreement”) in May 2014, as amended on March 26, 2015, with Cantor Fitzgerald & Co. (“Cantor”), as agent and/or principal, pursuant to which the Company could issue and sell, from time to time, shares of its common stock having an aggregate gross sales price of up to $18.0 million. The Company paid Cantor a commission of 3.0% of the gross proceeds from any common stock sold through the Sales Agreement. There were no proceeds from the Controlled Equity Offering during the twelve months ended December 31, 2016. The Sales Agreement expired in November 2016 upon the expiration of our Registration Statement on Form S-3. Stock Award Plans The Company has various stock plans that permit the Company to provide incentives to employees and directors of the Company in the form of equity compensation. In July 2012, the Compensation Committee of the Board of Directors adopted the 2012 S tock I ncentive P la n (the “Plan”) which was subsequently approved by the Company’s shareholders. This plan replaced the 2002 Stock Incentive Plan which expired on March 25, 2012. On June 5, 2013, June 10, 2014, and on May 24, 2016 the shareholders approved amendments to the Plan, which were previously approved and adopted by the Compensation Committee of the Board of Directors of the Company. Under each of the amendments on June 5, 2013 and June 10, 2014, the number of shares authorized for issuance under the Plan was increased by one million shares. The amendment on May 24, 2016 increased the number of shares authorized for issuance under the Plan by 1.5 million shares. At March 31, 2017 , the Company had 1,540,856 remaining shares of the Company’s common stock to provide for current and future grants under its various equity plans. At March 3 1 , 201 7 , the total compensation cost related to options, stock appreciation rights and non-vested stock granted to employees under the Company’s stock award plans but not yet recognized was approximately $1.1 million . This cost will be amortized over a period of up to four years over the underlying estimated service periods and will be adjusted for subsequent changes in actual forfeitures and anticipated vesting periods. A summary of the option and stock appreciat ion rights activity for the three month period ended March 31 , 201 7 is as follows:    Number of Options/SARs Range of Exercise Price Weighted Average Exercise Price per Share   Outstanding, December 31, 2016 671,887 $1.45 - $116.40 $8.77  Granted - -  Exercised - - -  Forfeited (6,410) $2.15 - $102.40 $45.80  Outstanding, March 31, 2017 665,477 $1.45 - $116.40 $8.41        A summary of the restricted stock unit activity for the three month period ended March 3 1 , 201 7 is as follows:    Number of Restricted Stock Units Weighted Average Grant Date Fair Value per Unit   Outstanding, December 31, 2016 1,167,099 $1.48  Granted 20,000 $0.71  Vested (466,487) $1.80  Forfeited (35,000) $1.49  Outstanding, March 31, 2017 685,612 $1.24 

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2017
Fair Value Measurements [Abstract]
Fair Value Measurements	11. Fair Value Measurements  The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). The three levels of the fair value hierarchy are described below: Level 1: Values are based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.  Level 2: Values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or other model-based valuation techniques for which all significant assumptions are observable in the market.  Level 3: Values are generated from model-based techniques that use significant assumptions not observable in the market.  The following table sets forth the Company’s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. As required by the Fair Value Measurements and Disclosures topic of the Accounting Standards Codification, assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.       Fair Value Measurement Using  Total Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3)  Liabilities at March 31, 2017:  Warrants issued May 2012 $ 12,731 — — 12,731  Warrants issued August 2013 103,429 — — 103,429  Warrants issued September 2016 16,541,539 — — 16,541,539  Total liabilities at fair value: $ 16,657,699 — — 16,657,699  Assets at December 31, 2016:  Cash equivalents $ — — — —  Total assets at fair value $ — — — —  Liabilities at December 31, 2016:  Warrants issued May 2012 $ 66,081 — — 66,081  Warrants issued August 2013 151,695 — — 151,695  Warrants issued September 2016 19,569,231 — — 19,569,231  Total liabilities at fair value: $ 19,787,007 — — 19,787,007  Level 1 The Company does not have any financial assets or liabilities classified as Level 1. Level 2 The Company does not have any financial assets or liabilities classified as Level 2. Level 3 In conjunction with the Company’s May 2012, August 2013 and September 2016 financing transactions, the Company issued warrants to purchase shares of the Company’s common stock. Due to the provisions included in the warrant agreements, the warrants did not meet the exemptions for equity classification and as such, the Company accounts for these warrants as derivative instruments. The calculated fair value of the warrants is classified as a liability and is periodically re-measured with any changes in value recognized in “Other income (expense)” in the Statements of Operations. The remaining warrants from the May 2012 transaction (PIPE Warrants) expire in May 2018 and were revalued as of March 31, 2017 using the following assumptions: 1) volatility of 96.06% ; 2) risk-free interest rate of 1.03% ; and 3) a closing stock price of $0.57 . The remaining warrants from the A ugust 2013 transaction (Exchange W arrants) expire in November 2018 and were re valued as of March 31, 2017 using the following assu mptions: 1) volatility of 113.29% ; 2) risk-free interest rate of 1.28% ; and 3 ) a closing stock price of $0.57 . The remaining warrants from the September 2016 transaction expire in September 2021 and were valued as of March 31 , 201 7 using the following assu mptions: 1) volatility of 120.29% ; 2) risk-free interest rate of 1.96% ; and 3) a closing stock price of $0.57 . The significant unobservable input used in the fair value measurement of the Company’s warrants is volatility. Significant increases (decreases) in the volatility in isolation would result in significantly higher (lower) liability fair value measurements.  The following table sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities for the three month period ended March 3 1, 2017 :      Warrants issued May 2012 Warrants issued August 2013 Warrants issued September 2016 Total Liabilities  Balance at beginning of period $ 66,081 $ 151,695 $ 19,569,231 $ 19,787,007  Issues - - - 0  Settlements - - - -  Revaluation (53,350) (48,266) (3,027,692) (3,129,308)  Balance at end of period $ 12,731 $ 103,429 $ 16,541,539 $ 16,657,699  The Company currently does not have derivative instruments to manage its exposure to currency fluctuations or other business risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. All derivative financial instruments are recognized in the balance sheet at fair value.

Product Warranty Provisions

Product Warranty Provisions	3 Months Ended
	Mar. 31, 2017
Product Warranty Provisions [Abstract]
Product Warranty Provisions	12. Product Warranty Provisions  The Company’s standard policy is to warrant all Niobe , Odyssey, and Vdrive systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability as appropriate.  Accrued warranty, which is included in other accrued liabilities, consists of the following:     March 31, 2017 December 31, 2016  Warranty accrual, beginning of the fiscal period $ 222,845 $ 316,835  Accrual adjustment for product warranty (19,612) 103,743  Payments made (10,169) (197,733)  Warranty accrual, end of the fiscal period $ 193,064 $ 222,845 

Commitments And Contingencies

Commitments And Contingencies	3 Months Ended
	Mar. 31, 2017
Commitments And Contingencies [Abstract]
Commitments And Contingencies	13. Commitments and Contingencies  The Company at times becomes a party to claims in the ordinary course of business. Management believes that the ultimate resolution of pending or threatened proceedings will not have a material effect on the financial position, results of operations or liquidity of the Company.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events None.    

Summary Of Significant Accoun20

Summary Of Significant Accounting Policies (Policy)	3 Months Ended
	Mar. 31, 2017
Summary Of Significant Accounting Policies [Abstract]
Basis Of Presentation	Basis of Presentation The accompanying unaudited financial statements of Stereotaxis, Inc. have been prepared in accordance with generally accepted accounting principles for interim financial information and the instructions to Form 10-Q. Accordingly, they do not include all the disclosures required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, they include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Operating results for the three month period ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ended December 31, 2017 or for future operating periods. These interim financial statements and the related notes should be read in conjunction with the annual financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the Securities and Exchange Commission (SEC) on March 16, 2017.
Financial Instruments	Financial Instruments Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value. The Company measures certain financial assets and liabilities, including warrants, at fair value on a recurring basis. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). See Note 11 for additional details.
Revenue And Costs Of Revenue	Revenue and Costs of Revenue The Company accounts for revenue using Accounting Standards Codification Topic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 permits management to estimate the selling price of undelivered components of a bundled sale for which it is unable to establish vendor-specific objective evidence (“VSOE”) or third-party evidence (“TPE”). This requires management to record revenue for certain elements of a transaction even though it might not have delivered other elements of the transaction, for which it was unable to meet the requirements for establishing VSOE or TPE. The Company believes that the guidance significantly improves the reporting of these types of transactions to more closely reflect the underlying economic circumstances. This guidance also prohibits the use of the residual method for allocating revenue to the various elements of a transaction and requires that the revenue be allocated proportionally based on the relative estimated selling prices. Under our revenue recognition policy, a portion of revenue for Niobe systems, Vdrive systems and certain Odyssey systems is recognized upon delivery, provided that title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. Revenue is recognized for other types of Odyssey systems upon completion of installation, since there are no qualified third party installers. When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since these arrangements do not include an installation element or right of return privileges. The Company does not recognize revenue in situations in which inventory remains at a Stereotaxis warehouse or in situations in which title and risk of loss have not transferred to the customer. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue. Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multiple-deliverable arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. We recognize revenue from disposable device sales or accessories upon shipment and establish an appropriate reserve for returns. The return reserve, which is applicable only to disposable devices, is estimated based on historical experience which is periodically reviewed and updated as necessary. In the past, changes in estimate have had only a de minimis effect on revenue recognized in the period. We believe that the estimate is not likely to change significantly in the future. Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred.
Share-Based Compensation	Share-Based Compensation The Company accounts for its grants of stock options, stock appreciation rights, restricted shares, and restricted stock units and for its employee stock purchase plan in accordance with the provisions of general accounting principles for share-based payments. These accounting principles require the determination of the fair value of the share-based compensation at the grant date and the recognition of the related expense over the period in which the share-based compensation vests. The Company utilizes the Black-Scholes valuation model to determine the fair value of stock options and stock appreciation rights at the date of grant. The resulting compensation expense is recognized over the requisite service period, which is generally four years. Restricted shares granted to employees are valued at the fair market value at the date of grant. The Company amortizes the fair market value to expense over the service period. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives.
Net Earnings (Loss) per Common Share ("EPS")	Net Earnings (Loss) per Common Share (“EPS”) Basic net income ( loss) per share is computed by dividing net income (loss) attributable to common shareholders by the number of common shares outstanding during the period. We apply the two-class method to calculate basic and diluted net income (loss) per share of common stock, as our Convertible Preferred Stock is a participating security. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been av ailable to common stockholders. In periods where there is a net loss, the two-class method of computing earnings per share does not apply as our Convertible Preferred Stock does not contractually participate in our losses. We compute diluted net income (loss) per common share using net income (loss) as the “control number” in determining whether potential common shares are dilutive, after giving consideration to all potentially dilutive common shares, including stock options, warrants, unvested restricted stock units outstanding during the period and potential issuance of stock upon the conversion of our Convertible Preferred Stock issued and outstanding during the period, except where the effect of such securities would be antidilutive. The following table sets forth the computation of basic and diluted EPS:    Three months ended March 31,  2017 2016  Net income (loss) $ 1,176,967 $ (2,274,301)  Cumulative dividend on convertible preferred stock (363,188) -  Net income attributable to convertible preferred stock (509,323) -  Earnings (net loss) attributable to common stockholders $ 304,456 $ (2,274,301)   Shares used for basic EPS-weighted average shares 22,318,000 21,611,612  Effect of dilutive securities: - -  Restricted Stock Units 13,683 -  Stock Options, Appreciation Rights and Warrants - -   Weighted average shares used in computing earnings (net loss) per share 22,331,683 21,611,612  Basic EPS $ 0.01 $ (0.11)  Diluted EPS $ 0.01 $ (0.11)  The following potential common shares were excluded from diluted EPS for the three months ended March 31, 2017 as they were antidilutive: 665,477 stock options and stock appreciation rights , 671, 929 restricted stock units, and 38,887,708 warrants . In addition, the Company did not include any portion of unearned restricted stock units, outstanding options, stock appreciation rights or warrants in the calculation of diluted loss per common share for the three months ended March 31, 2016 because all such securities are anti-dilutive for the period . The Company had no unearned restricted shares during either period. As of March 31, 2017, the Company had 665,477 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $8.41 per share, 38,887,708 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $0.83 per share, 37,892,041 shares of common stock issuable upon the conversion of Series A Convertible Preferred Stock and accumulated dividends at an exercise price of $0.65 per share, and 685,612 shares of unvested restricted share units.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU” or “Update”) No. 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.” This amendment is intended to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, forfeitures, and classification on the statement of cash flows. This update is effective for fiscal years beginning after December 15, 2016 (January 1, 2017 for the Company) and interim periods within those fiscal years, with earlier application permitted. The Company has adopted this guidance in the first quarter of 2017. The adoption of ASU 2016-09 did not materially impact the Company’s consolidated financial position, results of operations, equity or cash flows. In July 2015, the FASB issued ASU No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory” regarding the subsequent measurement of inventory as part of its Simplification Initiative. This standard is effective for public companies for fiscal years beginning after December 15, 2016 (January 1, 2017 for the Company), including interim periods within those fiscal years. This Update should be applied prospectively, and early application is permitted as of the beginning of an interim or annua l reporting period. The Company adopted this accounting standard update in the first quarter of 2017. The adoption of ASU 2015-1 1 did not materially impact the company ’s results of operations, financial conditions, cash flows, or financial statement presentation. In February 2016, the FASB issued ASU 2016-02, “Leases (ASC 842),” which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840 Leases. The standard is effective for interim and annual periods beginning after December 31, 2018 (January 1, 2019 for the Company), with early adoption permitted. The Company is in the process of evaluating the impact of this accounting standard update. In August 2014, the Financial Accounting Standards Board (“FASB”) issued AS U No. 2014-15, to communicate amendments to FASB Account Standards Codification Subtopic 205-40, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The ASU requires management to evaluate relevant conditions, events and certain management plans that are known or reasonably knowable as of the evaluation date when determining whether substantial doubt about an entity’s ability to continue as a going concern exists. Management will be required to make this evaluation for both annual and interim reporting periods. Management will have to make certain disclosures if it concludes that substantial doubt exists or when it plans to alleviate substantial doubt about the entity’s ability to continue as a going concern. The standard is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in the first quarter of 2017 (December 31, 2016 for the Company). Early adoption is permitted. The Company adopted this accounting standard update effective December 31, 2016 and provided the relevant disclosures in Note 1. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers,” which converges the FASB’s and the International Accounting Standards Board’s current standards on revenue recognition. The standard provides companies with a single model to use in accounting for revenue arising from contracts with customers and supersedes current revenue guidance. The standard is effective for annual and interim periods beginning after December 15, 2017 (January 1, 2018 for the Company). Early adoption is not permitted. The standard permits companies to either apply the adoption to all periods presented, or apply the requirements in the year of adoption through a cumulative adjustment. The Company will adopt ASU 2014-09 during the first quarter of 2018 and anticipates using the modified retrospective method that will result in a cumulative effect adjustment as of the date of adoption. Upon initial evaluation, management does not anticipate a significant change to its existing units of accounting which include systems, disposables and other accessories, royalty and other recurring revenue. The Company continues to evaluate other areas of the standard and its effect on the Corporation’s financial statements.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2017
Summary Of Significant Accounting Policies [Abstract]
Computation Of Basic And Diluted EPS	  Three months ended March 31,  2017 2016  Net income (loss) $ 1,176,967 $ (2,274,301)  Cumulative dividend on convertible preferred stock (363,188) -  Net income attributable to convertible preferred stock (509,323) -  Earnings (net loss) attributable to common stockholders $ 304,456 $ (2,274,301)   Shares used for basic EPS-weighted average shares 22,318,000 21,611,612  Effect of dilutive securities: - -  Restricted Stock Units 13,683 -  Stock Options, Appreciation Rights and Warrants - -   Weighted average shares used in computing earnings (net loss) per share 22,331,683 21,611,612  Basic EPS $ 0.01 $ (0.11)  Diluted EPS $ 0.01 $ (0.11) 

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2017
Inventories [Abstract]
Schedule Of Inventories	  March 31, 2017 December 31, 2016   Raw materials $ 2,476,142 $ 2,397,430  Work in process 349,597 341,125  Finished goods 3,126,728 2,915,162  Reserve for obsolescence (294,098) (272,614)  Total inventory $ 5,658,369 $ 5,381,103 

Prepaid Expenses And Other Cu23

Prepaid Expenses And Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2017
Prepaid Expenses And Other Current Assets [Abstract]
Schedule Of Prepaid Expenses And Other Current Assets	   March 31, 2017 December 31, 2016   Prepaid expenses $ 496,267 $ 575,886  Deferred financing costs 100,000 24,658  Deposits 356,956 293,992  Total prepaid expenses and other assets 953,223 894,536  Less: Noncurrent prepaid expenses and other assets (41,394) (39,241)  Total current prepaid expenses and other assets $ 911,829 $ 855,295 

Property And Equipment (Tables)

Property And Equipment (Tables)	3 Months Ended
	Mar. 31, 2017
Property And Equipment [Abstract]
Schedule Of Property And Equipment	  March 31, December 31,  2017 2016   Equipment $ 8,234,491 $ 8,397,528  Equipment held for lease 303,412 303,412  Leasehold improvements 2,714,486 2,719,860  11,252,389 11,420,800  Less: Accumulated depreciation (10,317,294) (10,334,556)  Net property and equipment $ 935,095 $ 1,086,244 

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2017
Accrued Liabilities [Abstract]
Schedule Of Accrued Liabilities	  March 31, December 31,  2017 2016   Accrued salaries, bonus, and benefits $ 2,274,587 $ 2,452,183  Accrued rent 723,770 965,412  Accrued licenses and maintenance fees 559,605 561,450  Accrued warranties 193,064 222,845  Accrued taxes 265,901 219,017  Accrued professional services 116,700 180,450  Other 272,614 210,216  Total accrued liabilities 4,406,241 4,811,573  Less: Long term accrued liabilities (320,545) (320,409)  Total current accrued liabilities $ 4,085,696 $ 4,491,164 

Deferred Revenue (Tables)

Deferred Revenue (Tables)	3 Months Ended
	Mar. 31, 2017
Deferred Revenue [Abstract]
Schedule Of Deferred Revenue	  March 31, December 31,  2017 2016   Product shipped, revenue deferred $ 467,383 $ 549,709  Customer deposits 2,910,000 2,910,000  Deferred service and license fees 6,433,038 5,813,956  Total deferred revenue 9,810,421 9,273,665  Less: Long-term deferred revenue (435,542) (522,329)  Total current deferred revenue $ 9,374,879 $ 8,751,336 

Convertible Preferred Stock A27

Convertible Preferred Stock And Stockholder's Equity (Tables)	3 Months Ended
	Mar. 31, 2017
Convertible Preferred Stock And Stockholders' Equity [Abstract]
Summary Of Option And Stock Appreciation Rights Activity	  Number of Options/SARs Range of Exercise Price Weighted Average Exercise Price per Share   Outstanding, December 31, 2016 671,887 $1.45 - $116.40 $8.77  Granted - -  Exercised - - -  Forfeited (6,410) $2.15 - $102.40 $45.80  Outstanding, March 31, 2017 665,477 $1.45 - $116.40 $8.41 
Summary Of Restricted Stock Unit Activity	  Number of Restricted Stock Units Weighted Average Grant Date Fair Value per Unit   Outstanding, December 31, 2016 1,167,099 $1.48  Granted 20,000 $0.71  Vested (466,487) $1.80  Forfeited (35,000) $1.49  Outstanding, March 31, 2017 685,612 $1.24 

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value Measurements [Abstract]
Assets And Liabilities Measured At Fair Value On Recurring Basis By Level	  Fair Value Measurement Using  Total Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3)  Liabilities at March 31, 2017:  Warrants issued May 2012 $ 12,731 — — 12,731  Warrants issued August 2013 103,429 — — 103,429  Warrants issued September 2016 16,541,539 — — 16,541,539  Total liabilities at fair value: $ 16,657,699 — — 16,657,699  Assets at December 31, 2016:  Cash equivalents $ — — — —  Total assets at fair value $ — — — —  Liabilities at December 31, 2016:  Warrants issued May 2012 $ 66,081 — — 66,081  Warrants issued August 2013 151,695 — — 151,695  Warrants issued September 2016 19,569,231 — — 19,569,231  Total liabilities at fair value: $ 19,787,007 — — 19,787,007 
Summary Of Changes In Fair Value Of Level 3 Financial Liabilities	  Warrants issued May 2012 Warrants issued August 2013 Warrants issued September 2016 Total Liabilities  Balance at beginning of period $ 66,081 $ 151,695 $ 19,569,231 $ 19,787,007  Issues - - - 0  Settlements - - - -  Revaluation (53,350) (48,266) (3,027,692) (3,129,308)  Balance at end of period $ 12,731 $ 103,429 $ 16,541,539 $ 16,657,699 

Product Warranty Provisions (Ta

Product Warranty Provisions (Tables)	3 Months Ended
	Mar. 31, 2017
Product Warranty Provisions [Abstract]
Schedule Of Accrued Warranty	  March 31, 2017 December 31, 2016  Warranty accrual, beginning of the fiscal period $ 222,845 $ 316,835  Accrual adjustment for product warranty (19,612) 103,743  Payments made (10,169) (197,733)  Warranty accrual, end of the fiscal period $ 193,064 $ 222,845 

Summary Of Significant Accoun30

Summary Of Significant Accounting Policies (Narrative) (Details) - $ / shares	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants	$ 0.70
Stock Options And Stock Appreciation Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, requisite service period	4 years
Options and stock appreciation rights outstanding	665,477	671,887
Weighted average exercise price	$ 8.41	$ 8.77
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issuable upon exercise	38,887,708
Exercise price of warrants	$ 0.83
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested restricted shares	685,612	1,167,099
Stock Options And Stock Appreciation Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	665,477
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	671,929
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	38,887,708
Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issuable upon exercise	37,892,041
Exercise price of warrants	$ 0.65

Summary Of Significant Accoun31

Summary Of Significant Accounting Policies (Computation Of Basic And Diluted EPS) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Summary Of Significant Accounting Policies [Abstract]
Net earnings (loss)	$ 1,176,967	$ (2,274,301)
Cumulative dividend on convertible preferred stock	(363,188)
Net income attributable to convertible preferred stock	(509,323)
Earnings (net loss) attributable to common stockholders	$ 304,456	$ (2,274,301)
Shares used for basic EPS-weighted average shares	22,318,000	21,611,612
Effect of diluted securities: Restricted stock units	13,683
Weighted average shares used in computing earnings (net loss) per share	22,331,683	21,611,612
Basic EPS	$ 0.01	$ (0.11)
Diluted EPS	$ 0.01	$ (0.11)

Inventories (Details)

Inventories (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Inventories [Abstract]
Raw materials	$ 2,476,142	$ 2,397,430
Work in process	349,597	341,125
Finished goods	3,126,728	2,915,162
Reserve for obsolescence	(294,098)	(272,614)
Total inventory	$ 5,658,369	$ 5,381,103

Prepaid Expenses And Other Cu33

Prepaid Expenses And Other Current Assets (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Prepaid Expenses And Other Current Assets [Abstract]
Prepaid expenses	$ 496,267	$ 575,886
Deferred financing costs	100,000	24,658
Deposits	356,956	293,992
Total prepaid expenses and other assets	953,223	894,536
Less: Noncurrent prepaid expenses and other assets	(41,394)	(39,241)
Total current prepaid expenses and other assets	$ 911,829	$ 855,295

Property And Equipment (Details

Property And Equipment (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 11,252,389	$ 11,420,800
Less: Accumulated depreciation	(10,317,294)	(10,334,556)
Net property and equipment	935,095	1,086,244
Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	8,234,491	8,397,528
Equipment Held For Lease [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	303,412	303,412
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 2,714,486	$ 2,719,860

Intangible Assets (Details)

Intangible Assets (Details)	Mar. 31, 2017USD ($)
Intangible Assets [Abstract]
Total intangible assets	$ 3,221,069
Accumulated amortization	$ 2,834,331

Accrued Liabilities (Narrative)

Accrued Liabilities (Narrative) (Details)	3 Months Ended
	Mar. 31, 2017USD ($)ft²	Jan. 31, 2017USD ($)ft²	Dec. 31, 2016USD ($)	Aug. 31, 2016USD ($)ft²	Dec. 31, 2015ft²	Sep. 30, 2013USD ($)ft²
Real Estate [Line Items]
Accrued costs of rent liability	$ 723,770		$ 965,412
Office [Member]
Real Estate [Line Items]
Square feet of leased space | ft²	52,000				3,152
Sublease expiration date	Dec. 31, 2018
Demonstration And Assembly [Member]
Real Estate [Line Items]
Square feet of leased space | ft²	12,000
Unimproved [Member]
Real Estate [Line Items]
Square feet of leased space | ft²						13,000
Accrued lease termination costs remaining	$ 160,065
Accrued costs of rent liability						$ 515,138
Office Sublease [Member]
Real Estate [Line Items]
Square feet of leased space | ft²				11,000
Accrued lease termination costs remaining	$ 44,687
Sublease expiration date	Dec. 31, 2018
Accrued costs of rent liability				$ 40,972
Office Sublease, January 2017 [Member]
Real Estate [Line Items]
Square feet of leased space | ft²		16,000
Sublease expiration date	Dec. 31, 2018
Accrued costs of rent liability		$ 28,208

Accrued Liabilities (Schedule O

Accrued Liabilities (Schedule Of Accrued Liabilities) (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accrued Liabilities [Abstract]
Accrued salaries, bonus, and benefits	$ 2,274,587	$ 2,452,183
Accrued rent	723,770	965,412
Accrued licenses and maintenance fees	559,605	561,450
Accrued warranties	193,064	222,845	$ 316,835
Accrued taxes	265,901	219,017
Accrued professional services	116,700	180,450
Other	272,614	210,216
Total accrued liabilities	4,406,241	4,811,573
Less: Long term accrued liabilities	(320,545)	(320,409)
Total current accrued liabilities	$ 4,085,696	$ 4,491,164

Deferred Revenue (Details)

Deferred Revenue (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	$ 9,810,421	$ 9,273,665
Less: Long-term deferred revenue	(435,542)	(522,329)
Total current deferred revenue	9,374,879	8,751,336
Product Shipped, Revenue Deferred [Member]
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	467,383	549,709
Customer Deposits [Member]
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	2,910,000	2,910,000
Deferred Service And License Fees [Member]
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	$ 6,433,038	$ 5,813,956

Long-Term Debt And Credit Fac39

Long-Term Debt And Credit Facilities (Narrative) (Details)	Jan. 31, 2013USD ($)	Aug. 08, 2012USD ($)	Sep. 30, 2016USD ($)	Nov. 30, 2011USD ($)	Mar. 31, 2017USD ($)	Sep. 30, 2016USD ($)	Dec. 31, 2016USD ($)	May 10, 2016USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Debt Instrument [Line Items]
Cash and cash equivalents					$ 5,739,124		$ 8,501,392		$ 1,602,951	$ 5,593,582
Payments of debt							$ 13,000,000
Healthcare Royalty Partners Debt [Member]
Debt Instrument [Line Items]
Amount of debt extinguished			$ 18,100,000
Deferred financing costs			300,000			$ 300,000
Accrued interest			500,000			500,000
Payments of debt			$ 13,000,000
Gain on debt extinguishment						$ 5,600,000
Term Loan [Member] | Healthcare Royalty Partners Debt [Member]
Debt Instrument [Line Items]
Amount borrowed	$ 2,500,000	$ 2,500,000		$ 15,000,000
Additional amount which may be borrowed				$ 5,000,000
Percentage of royalties entitled to receive				100.00%
Maturity date					Dec. 31, 2018
Annual interest rate				16.00%
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity					$ 10,000,000
Line of credit facility, maturity date					Mar. 31, 2018
Minimum tangible net worth requirement, period one								$ (24,000,000)
Minimum tangible net worth requirement, period two								$ (24,500,000)
Total liquidity					$ 10,000,000
Line of credit facility, amount outstanding					0
Line of credit facility, current borrowing capacity					$ 4,300,000
Minimum [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Liquidity ratio								1.50

Convertible Preferred Stock A40

Convertible Preferred Stock And Stockholders' Equity (Narrative) (Details)	Sep. 29, 2016USD ($)shares	May 24, 2016shares	Jun. 10, 2014shares	Jun. 05, 2013shares	Sep. 30, 2016USD ($)	May 31, 2014USD ($)	Mar. 31, 2017USD ($)$ / sharesitemshares	Mar. 31, 2016USD ($)	Dec. 31, 2016USD ($)$ / sharesshares
Shareholders' Equity and Share-based Payments [Line Items]
Votes per share | item							1
Dividends declared							$ 0
Dividends paid							$ 0
Proceeds from preferred stock and warrants issued, gross	$ 24,000,000
Preferred stock, shares issued | shares	24,000
Preferred stock, par value | $ / shares							$ 0.001		$ 0.001
Preferred Stock, Liquidation Preference, Value							$ 1,000
Common stock issuable from warrants | shares	36,923,078
Proceeds from preferred stocks and warrants, net									$ 23,000,000
Payments of debt									13,000,000
Preferred stock dividend rate							6.00%
Preferred stock, conversion price | $ / shares							$ 0.65
Preferred stock redemption, triggering event, Percent of common stock sold threshold							50.00%
Preferred stock, Accretion of dicount									$ 6,100,000
Exercise price of warrants | $ / shares							$ 0.70
Warrant term							180 days
Proceeds from issuance of stock, net of issuance costs							$ 9,336	$ 7,392
Increase in number of shares authorized for issuance under the Plan | shares		1,500,000	1,000,000	1,000,000
Total compensation cost not yet recognized							$ 1,100,000
Weighted average amortization period of total compensation cost not yet recognized							4 years
Remaining shares available for issuance | shares							1,540,856
Convertible Preferred Stock [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Shares converted | shares									100
Common Stock [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Shares issued in conversion | shares									155,439
Sales Agreement [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Aggregate gross sales price						$ 18,000,000
Commission percentage of gross proceeds						3.00%
Proceeds from issuance of stock, net of issuance costs									$ 0
Warrants [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Exercise price of warrants | $ / shares							$ 0.83
Restricted Stock Units [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Restricted shares outstanding | shares							685,612		1,167,099
Healthcare Royalty Partners Debt [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Payments of debt					$ 13,000,000

Convertible Preferred Stock A41

Convertible Preferred Stock And Stockholders' Equity (Summary Of Option And Stock Appreciation Rights Activity) (Details) - Stock Options And Stock Appreciation Rights [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options/SARs, Outstanding, December 31, 2016	671,887
Number of Options/SARs, Granted
Number of Options/SARs, Exercised
Number of Options/SARs, Forfeited	(6,410)
Number of Options/SARs, Outstanding, March 31, 2017	665,477	671,887
Weighted Average Exercise Price per Share, Outstanding, December 31, 2016	$ 8.77
Weighted Average Exercise Price per Share, Granted
Weighted Average Exercise Price per Share, Exercised
Weighted Average Exercise Price per Share, Forfeited	45.80
Weighted Average Exercise Price per Share, Outstanding, March 31, 2017	8.41	$ 8.77
$1.45 - $116.40 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit		1.45
Range of Exercise Price, Upper Limit		$ 116.40
$2.15 - $102.40 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit	2.15
Range of Exercise Price, Upper Limit	102.40
$1.45 - $116.40 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit	1.45
Range of Exercise Price, Upper Limit	$ 116.40

Convertible Preferred Stock A42

Convertible Preferred Stock And Stockholders' Equity (Summary Of Restricted Stock Unit Activity) (Details) - Restricted Stock Units [Member]	3 Months Ended
	Mar. 31, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Restricted Stock Units, Outstanding, December 31, 2016 | shares	1,167,099
Number of Restricted Stock Units, Granted | shares	20,000
Number of Restricted Stock Units, Vested | shares	(466,487)
Number of Restricted Stock Units, Forfeited | shares	(35,000)
Number of Restricted Stock Units, Outstanding, March 31, 2017 | shares	685,612
Weighted Average Grant Date Fair Value per Unit, Outstanding, December 31, 2016 | $ / shares	$ 1.48
Weighted Average Grant Date Fair Value per Unit, Granted | $ / shares	0.71
Weighted Average Grant Date Fair Value per Unit, Vested | $ / shares	1.80
Weighted Average Grant Date Fair Value per Unit, Forfeited | $ / shares	1.49
Weighted Average Grant Date Fair Value per Unit, Outstanding, March 31, 2017 | $ / shares	$ 1.24

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Financial assets
Financial liabilities	$ 16,657,699	19,787,007
Quoted Prices In Active Markets For Identical Instruments (Level 1) [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Financial assets
Financial liabilities
Significant Other Observable Inputs (Level 2) [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Financial assets
Financial liabilities
Significant Unobservable Inputs (Level 3) [Member] | Warrants Issued September 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant expiration date	Sep. 1, 2021
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Financial assets
Financial liabilities	$ 16,657,699	$ 19,787,007
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member] | Warrants Issued May 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant expiration date	May 1, 2018
Volatility rate	96.06%
Risk-free interest rate	1.03%
Closing stock price	$ 0.57
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member] | Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant expiration date	Nov. 1, 2018
Volatility rate	113.29%
Risk-free interest rate	1.28%
Closing stock price	$ 0.57
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member] | Warrants Issued September 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Volatility rate	120.29%
Risk-free interest rate	1.96%
Closing stock price	$ 0.57

Fair Value Measurements (Assets

Fair Value Measurements (Assets And Liabilities Measured At Fair Value On Recurring Basis By Level) (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Total assets at fair value
Warrants issued	$ 16,657,699	19,787,007
Total liabilities at fair value	16,657,699	19,787,007
Warrants Issued May 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	12,731	66,081
Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	103,429	151,695
Warrants Issued September 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	16,541,539	19,569,231
Quoted Prices In Active Markets For Identical Instruments (Level 1) [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Total assets at fair value
Total liabilities at fair value
Quoted Prices In Active Markets For Identical Instruments (Level 1) [Member] | Recurring [Member] | Warrants Issued May 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Quoted Prices In Active Markets For Identical Instruments (Level 1) [Member] | Recurring [Member] | Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Quoted Prices In Active Markets For Identical Instruments (Level 1) [Member] | Recurring [Member] | Warrants Issued September 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Significant Other Observable Inputs (Level 2) [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Total assets at fair value
Total liabilities at fair value
Significant Other Observable Inputs (Level 2) [Member] | Recurring [Member] | Warrants Issued May 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Significant Other Observable Inputs (Level 2) [Member] | Recurring [Member] | Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Significant Other Observable Inputs (Level 2) [Member] | Recurring [Member] | Warrants Issued September 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Total assets at fair value
Total liabilities at fair value	16,657,699	19,787,007
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member] | Warrants Issued May 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	12,731	66,081
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member] | Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	103,429	151,695
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member] | Warrants Issued September 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	$ 16,541,539	$ 19,569,231

Fair Value Measurements (Summar

Fair Value Measurements (Summary Of Changes In Fair Value Of Level 3 Financial Liabilities) (Details)	3 Months Ended
	Mar. 31, 2017USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	$ 19,787,007
Issues
Settlements
Revaluation	(3,129,308)
Balance at end of period	16,657,699
Warrants Issued May 2012 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	66,081
Issues
Settlements
Revaluation	(53,350)
Balance at end of period	12,731
Warrants Issued August 2013 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	151,695
Issues
Settlements
Revaluation	(48,266)
Balance at end of period	103,429
Warrants Issued September 2016 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	19,569,231
Issues
Settlements
Revaluation	(3,027,692)
Balance at end of period	$ 16,541,539

Product Warranty Provisions (De

Product Warranty Provisions (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Product Warranty Provisions [Abstract]
Standard product warranty coverage term	1 year
Warranty accrual, beginning of the fiscal period	$ 222,845	$ 316,835
Accrual adjustment for product warranty	(19,612)	103,743
Payments made	(10,169)	(197,733)
Warranty accrual, end of the fiscal period	$ 193,064	$ 222,845